Fenfluramine

Fenfluramine

SCHEMBL16215

CCNC(C)Cc1cccc(C(F)(F)F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HTR1DHTR2CSIGMAR1

The experimentally established mechanism targets of Fenfluramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 known ✓ Q99720 4/20 1.00
HTR2C known ✓ P28335 4/20 0.64
HTR1D known ✓ P28221 1/20 0.43
SLC6A4 P31645 6/20 1.00
HTR2A P28223 4/20 1.00
HTR2B P41595 4/20 1.00
ADRA2C P18825 4/20 1.00
DRD3 P35462 4/20 1.00
ADRA1A P35348 2/20 1.00
OPRK1 P41145 2/20 1.00
LMNA P02545 1/20 1.00
MAPT P10636 1/20 1.00
CYP3A4 P08684 3/20 0.67
CYP2D6 P10635 3/20 0.67
CYP1A2 P05177 2/20 0.67
TP53 P04637 1/20 0.67
TSHR P16473 1/20 0.67
CYP2C19 P33261 1/20 0.67
SLC6A2 P23975 3/20 0.57
OPRM1 P35372 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dexfenfluramine SCHEMBL16706 1.00 SLC6A4 (1.00) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Dexfenfluramine SCHEMBL15669714 1.00 SLC6A4 (1.00) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Fenfluramine SCHEMBL29447403 1.00 SLC6A4 (1.00) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Dexfenfluramine SCHEMBL29499611 1.00 SLC6A4 (1.00) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Levofenfluramine SCHEMBL162006 1.00 SLC6A4 (1.00) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Levofenfluramine SCHEMBL29882976 1.00 SLC6A4 (1.00) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Fenfluramine SCHEMBL23724055 0.98 SLC6A4 (0.97) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Fenfluramine SCHEMBL11140094 0.98 SLC6A4 (0.97) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Fenfluramine SCHEMBL39491 0.98 SLC6A4 (0.97) SLC6A4SIGMAR1HTR2AHTR2BADRA2C
Levofenfluramine SCHEMBL30951308 0.98 SLC6A4 (0.97) SLC6A4SIGMAR1HTR2AHTR2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 19989 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094963-A Cardioprotective lipids and methods of use 2026-05-26 CN claimed
WO-2026107229-A1 REDUCING THE ADDICTIVE LIABILITY OF OPIOID ANALGESICS BY CO- ADMINISTERING 5HT2 RECEPTOR AGONISTS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-05-21 WO claimed
US-20260137654-A1 COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER THE REGENTS OF THE UNIV OF CALIFORNIA (US) 2026-05-21 US claimed
US-12617809-B2 Cardioprotective lipid and method of use SIGNPATH PHARMA, INC. (US) 2026-05-05 US claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
US-20260083706-A1 5HT AGONISTS FOR TREATING DISORDERS UNIV CALIFORNIA (US) 2026-03-26 US claimed
US-20260076971-A1 METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2026-03-19 US claimed
EP-4696377-A2 5HT AGONISTS FOR TREATING DISORDERS The Regents of the University of California (US) 2026-02-18 EP claimed
US-20260027139-A1 TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST VIVUS, INC. 2026-01-29 US claimed
US-20250367203-A1 METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2025-12-04 US claimed
WO-1990004387-A2 COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1990-05-03 WO claimed
US-4857553-A SIDE EFFECT REDUCTION A. H. ROBINS COMPANY, INCORPORATED (US) 1989-08-15 US claimed
WO-1989003692-A1 TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-05-05 WO claimed
EP-0308317-A1 Chewable anorectic composition and process to prepare it SANOFI (FR) 1989-03-22 EP claimed
EP-0302757-A2 Anti-emetic serotonin depleting agents A.H. ROBINS COMPANY, INCORPORATED (US) 1989-02-08 EP claimed
EP-0253146-A2 The use of D-Fenfluramine for the manufacture of medicaments for treating depression MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1988-01-20 EP claimed
US-4649161-A Method for treating depression with d-fenfluramine MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1987-03-10 US claimed
US-4557934-A ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE THE PROCTER & GAMBLE COMPANY (US) 1985-12-10 US claimed
US-4309445-A d-Fenfluramine for modifying feeding behavior MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1982-01-05 US claimed
US-4255439-A Means and method for aiding individuals to stop smoking COOPER IRVING 1981-03-10 US claimed